

**Litteraturliste - Mutationsundersøgelser mhp. anti-EGFR  
behandling**Forfattere: Louise Klarskov, Jan  
Lindebjerg, Lars Henrik Jensen

Gælder fra: 1. juni 2016

Gælder til:

1. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E et al. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. *J Clin Oncol.* 2008 Jan 20;26(3):374-9
2. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. *Ann Intern Med.* 2011 Jan 4;154(1):37-49
3. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010; 11: 753-62
4. Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. *NEJM* 2013 369: 1023-34
5. Baas JM, Krens LL, Guchelaar HJ, Morreau H, Gelderblom H. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. *Oncologist.* 2011;16(9):1239-49
6. Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. *Br J Cancer.* 2011 Mar 15;104(6):1020-6
7. Toon CW, Chou A, DeSilva K, Chan J, Patterson J, Clarkson A, et al. BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer. *Mod Pathol.* 2014 May;27(5):644-50